NPI registry status
Active
2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1568428134 MD
Verify on CMS → Mohamad Al Sayed, MD
Endocrinology, Diabetes & Metabolism Physician in Riverside, California.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 7,852 in Endocrinology, Diabetes & Metabolism Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
621
Medicare Part D claims · 91 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
38%
generic claims · 54% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
100/100
▲ 17 pts above national avg 83.1 · Exceptional
Industry payments
$319.55
10 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2023
Compiled from official public sources by the PlainDoctor editorial team.
What the federal data shows
Mohamad Al Sayed, MD reported a CMS MIPS final score of 100/100 - above the 83.1 national average - and filed 621 Medicare Part D claims in 2023.
- 100/100
- MIPS score · +17 vs avg
- 621
- Part D claims, 2023
- 38%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Mohamad Al Sayed, MD's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure
100 Top 7% higher than 93% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Mohamad Al Sayed, MD sits
This provider among endocrinology, diabetes & metabolism physician peers
Across the 2,521 endocrinology, diabetes & metabolism physician providers who report both Medicare Part D prescribing and a MIPS quality score, Mohamad Al Sayed, MD writes more Part D claims than 18% of them and scores higher on MIPS quality than 93% - placing this provider in the lower-volume, high-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one endocrinology, diabetes & metabolism physician peer from a representative sample of 60; the gold marker is Mohamad Al Sayed, MD. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Mohamad Al Sayed, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Mohamad Al Sayed, MD?
High performer (top quartile)Primary specialty
Endocrinology, Diabetes & Metabolism Physician
Medicare Part D claims
621 76% vs specialty avg
MIPS final score
100/100 16.9 pts vs avg
Specialty distribution in California
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among California providers
Medicare quality performance, MIPS
Mohamad Al Sayed, MD's 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average
- MIPS Final Score
- 100/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Endocrinology, Diabetes & Metabolism Physician) - 100/100 vs national avg 83.1
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Mohamad Al Sayed, MD appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding MD credentials at 4234 RIVERWALK PKWY STE 230, Riverside, CA, 92505, with a listed phone of (951) 373-5819. NPI 1568428134 was issued on 04/24/2006.
Medicare Part D records for calendar year 2023 show 621 prescription claims written by this provider, covering 91 Medicare beneficiaries and totaling roughly $298K in drug spend, split 54% brand-name and 38% generic by claim count. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 100/100 for the 2023 performance year (Quality 100, Cost 90.1), compared with the national average of 83.1.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1568428134 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | MD |
| Gender | Male |
| NPI Issued | 04/24/2006 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
100
Final Score
Avg: 83.1
100
Quality
90.1471
Cost
87
Promoting Interoperability
Reporting: Group practice
Hospital and facility affiliations
Facilities where Mohamad Al Sayed, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Chaparral Medical Group Inc
Rancho Cucamonga, CA
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Mohamad Al Sayed, MD. Source: openpaymentsdata.cms.gov.
Total received
$320
Largest payer
Lilly USA, LLC
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - California MBC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 - they are NOT specific to Mohamad Al Sayed, MD. To verify Mohamad Al Sayed, MD's current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
Mohamad Al Sayed, MD - brand share 54.0%
Endocrinology, Diabetes & Metabolism Physician average
54% brand-name claims vs 38% generic, on 621 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
621
Total Claims
$298K
Total Drug Cost
91
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 1,145
- Total Day Supply
- 33,549
- Brand vs Generic
- 54% brand / 38% generic
- Brand Drug Cost
- $292K
- Generic Drug Cost
- $4K
Patient Demographics
- Average Patient Age
- 67.9 years
- Avg HCC Risk Score
- 1.64
- Gender Split
- 57% female / 43% male
- Age Distribution
- <65: 20, 65-74: 55, 75-84: N/A, 85+: N/A
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Mohamad Al Sayed, MD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Trulicity
Trulicity
123 claims
- Levothyroxine Sodium 44
Levothyroxine Sodium
44 claims
- Atorvastatin Calcium 27
Atorvastatin Calcium
27 claims
- Rybelsus 26
Rybelsus
26 claims
- Glipizide Er 23
Glipizide Er
23 claims
- Novolog Flexpen 23
Novolog Flexpen
23 claims
- Hydrochlorothiazide 19
Hydrochlorothiazide
19 claims
- Jardiance 18
Jardiance
18 claims
| Drug | Claims |
|---|---|
| Trulicity Dulaglutide | 123 |
| Levothyroxine Sodium | 44 |
| Atorvastatin Calcium | 27 |
| Rybelsus Semaglutide | 26 |
| Glipizide Er Glipizide | 23 |
| Novolog Flexpen Insulin Aspart | 23 |
| Hydrochlorothiazide | 19 |
| Jardiance Empagliflozin | 18 |
| Metformin Hcl | 17 |
| Ozempic Semaglutide | 17 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
More Endocrinology, Diabetes & Metabolism Physician in CA →
All providers in California →
Compare specialties →
Endocrinology, Diabetes & Metabolism Physician Overview
How Mohamad Al Sayed, MD fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
7,852
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,639
Avg Claims per Provider
Mohamad Al Sayed, MD's 621 claims are below the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as Al Sayed.
Dr. Anita Abraham
M.D.
Stockton, CA
Dr. Sallie Adams
M.D.
Roseville, CA
Ananta Addala
Palo Alto, CA
Dr. Helen Adelberg
M.D.
Encino, CA
Dr. David Aftergood
MD
Beverly Hills, CA
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the California medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Endocrinology, Diabetes & Metabolism Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore California
Frequently Asked Questions
What is Mohamad Al Sayed, MD's specialty? ▼
Mohamad Al Sayed, MD specializes in Endocrinology, Diabetes & Metabolism Physician and practices in Riverside, California. Credentials: MD.
How much does Mohamad Al Sayed, MD prescribe under Medicare Part D? ▼
In 2023, Mohamad Al Sayed, MD wrote 621 Medicare Part D claims totaling $298K in drug costs for 91 beneficiaries.
What is Mohamad Al Sayed, MD's Medicare quality score? ▼
Mohamad Al Sayed, MD has a CMS MIPS Final Score of 100/100 (Quality: 100, Cost: 90.1). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Mohamad Al Sayed, MD located? ▼
Mohamad Al Sayed, MD is located at 4234 RIVERWALK PKWY STE 230, Riverside, CA, 92505. Phone: (951) 373-5819.
What is Mohamad Al Sayed, MD's NPI number? ▼
Mohamad Al Sayed, MD's National Provider Identifier (NPI) is 1568428134, issued on 04/24/2006.
Does Mohamad Al Sayed, MD prescribe more brand-name or generic drugs? ▼
Mohamad Al Sayed, MD's prescribing is 54% brand-name and 38% generic drugs by claim count, with $292K in brand drug costs.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
There are 7,852 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,639 Medicare Part D claims per year.
What drugs does Mohamad Al Sayed, MD prescribe most often? ▼
Based on 2023 Medicare Part D data, Mohamad Al Sayed, MD's most frequently prescribed drugs include Trulicity, Levothyroxine Sodium, Atorvastatin Calcium. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Mohamad Al Sayed, MD accept Medicare? ▼
Mohamad Al Sayed, MD appears in CMS Medicare data with 621 Part D claims and 91 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Mohamad Al Sayed, MD's credentials? ▼
Mohamad Al Sayed, MD's NPI is 1568428134 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Compiled from official public sources by the PlainDoctor editorial team.